🧪 So far, most rAAV-based therapies have been developed using human embryo kidney 293 (HEK293) cells.
🐹 However, a team at Genentech has successfully produced rAAV using Chinese hamster ovary (CHO) cells, which could be a new option for manufacturing these drugs.
💡 Other cell types, such as insect cells, are also being explored for rAAV production.
🌐 The search for the best cell type for manufacturing rAAV-based drugs continues, but CHO cells may be a promising option.
Introduction:
Recombinant adeno-associated viruses (rAAVs) are in high demand for gene therapy applications. However, efficient manufacture of rAAV vectors remains challenging. The use of different cell types for rAAV production is being explored to meet this demand. This article discusses the use of Chinese hamster ovary (CHO) cells as an alternative to human embryo kidney (HEK293) cells for rAAV production.
- The field of gene therapy has advanced with the approval of five rAAV-based products by the FDA.
- The use of CHO cells in rAAV production was explored as an alternative to HEK293 cells.
- The Genentech team successfully produced comparable levels of viral particles using CHO cells.
- Other studies have also compared different cell types for rAAV production, suggesting that insect cells may be preferred over HEK293 cells.
- CHO cells have been widely used in biomolecule manufacturing and could be a promising cell source for rAAV production.
Conclusion:
Manufacturing rAAV-based drugs is a growing field, and the choice of cell type for production remains uncertain. The use of CHO cells shows promise as an alternative to HEK293 cells, and further research is needed to determine the optimal cell source for rAAV production. CHO cells have a long history of use in biomolecule manufacturing, which makes them a potential candidate for future gene therapies.
